Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This educational activity is supported by educational grants from Eisai, Inc.; Exelixis, Inc.; and Merck & Co., Inc.

Integrating the Evidence to Optimize Treatment for Patients with Advanced RCC: An Expert Tumor Board Discussion

Release Date: June 30, 2020
Expiration Date: June 30, 2021

Activity Overview

Integrating the Evidence to Optimize Treatment for Patients With Advanced RCC: An Expert Tumor Board Discussion is an online, on-demand virtual symposium that was filmed after the 2020 ASCO annual meeting in Chicago. In this activity, an esteemed faculty of renowned experts in advanced renal cell carcinoma (RCC) lead an in-depth, real-world tumor board discussion of the clinical impact of recent and emerging data from clinical studies of advanced RCC treatment. A series of tightly integrated case presentations illuminate RCC treatment decisions related to sequencing and switching based on patient and disease characteristics, as well as adverse event monitoring, mitigation, and management. Additionally, the faculty addresses how anticipated developments may soon shape how you care for your patients. Do not miss this opportunity to learn how to apply the latest data and improve your practice!

Acknowledgment of Commercial Support

This educational activity is supported by educational grants from Eisai, Inc.; Exelixis, Inc.; and Merck & Co., Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of RCC. Urologists, nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with RCC will also be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Review the pathobiology of RCC, and the therapeutic rationales for using targeted therapies and immunotherapies, both as single agents and in combination regimens
  • Assess new and practice-changing data from clinical trials evaluating systemic agents such as targeted therapies and immunotherapies across multiple lines of therapy for advanced/metastatic RCC
  • Outline strategies to monitor and mitigate adverse events associated with targeted agents and immunotherapies used in the treatment of advanced/metastatic RCC
  • Consider the efficacy and safety of systemic therapies, as well as biomarkers, disease characteristics, comorbidities, and patient preferences, in order to individualize and optimize treatment for patients with advanced/metastatic RCC

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Toni K. Choueiri, MD
Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Jerome and Nancy Kohlberg Chair and Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: Analysis Group, AstraZeneca, Alexion, Bayer, Bristol Myers Squibb/ER Squibb and Sons LLC, Cerulean, Eisai, Inc, Foundation Medicine Inc, Exelixis, Inc, Ipsen, TRACON, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Sanofi- Aventis, Takeda; Consultant: Analysis Group, AstraZeneca, Alexion, Sanofi-Aventis, Bayer, Bristol Myers Squibb/ER Squibb and Sons, LLC, Cerulean, Eisai, Inc, Foundation Medicine Inc, Exelixis, Inc, Genentech, Heron Therapeutics, Inc, Lilly, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, National Comprehensive Cancer Network.

Robert A. Figlin, MD, FACP
Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Deputy Director, Cedars-Sinai Cancer
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosures: Grant Research Support: Exelixis, Inc, Calithera, Merck, Bristol Myers Squibb; Consultant: Merck, Arrowhead, Bristol Myers Squibb, Eisai, Inc, Apollomics, Inc.

David F. McDermott, MD
David F. McDermott, MD
Chief, Medical Oncology, Beth Israel Deaconess Medical Center
Leader, Dana Farber/Harvard Cancer Center Kidney Cancer Program
Professor of Medicine, Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: BMS, Pfizer, Merck, Alkermes, Inc, Genentech, X4 Pharmaceuticals, Exelixis, Inc; Consultant: BMS, Pfizer, Merck, Alkermes, Inc, EMD Serono, Eli Lilly and Company, Iovance, Eisai, Inc.

Rana R. McKay, MD
Rana R. McKay, MD
Assistant Professor of Medicine
University of California San Diego
La Jolla, CA

Disclosures: Grant Research Support: Pfizer, Bayer; Consultant: Exelixis, Inc, BMS, Dendreon, Vividion, Tempus, JNJ, Pfizer, Bayer, Sanofi, Novartis.

Sumanta K. Pal, MD
Sumanta K. Pal, MD
Clinical Professor
Department of Medical Oncology & Experimental Therapeutics
City of Hope Comprehensive Cancer Center
Chair, SWOG Renal Cancer Center Translational Medicine
Duarte, CA

Disclosures: Grant Research Support: Pfizer, Bayer; Consultant: Exelixis, Inc, BMS, Dendreon, Vividion, Tempus, JNJ, Pfizer, Bayer, Sanofi, Novartis.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By